Abstract: Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, bispecific antibodies are disclosed that are able to engage T-cells to destroy TAG-72-expressing malignant cells.

Abstract: Disclosed are compositions and methods for targeted treatment of glioblastoma multiforme (GBM). In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill Glioblastoma Stem Cells (GSCs). Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with Glioblastoma Stem Cells (GSCs) that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

Abstract: A method of identifying cancer patients who would be responsive to bladder sparing surgery plus chemoradiation therapy or cystectomy using expression of MRE11 in a nuclear to cytoplasmic ratio is presented.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium are provided, including a method for presenting information for treating patients. The method comprises presenting, in a user interface, a pathway for use in treating a patient with a disease and including a combination of therapeutic and diagnostic pathway elements including an integration of diagnostic, radiation, chemotherapy, surgical and other elements. The method further comprises augmenting the pathway including providing controls for accessing additional information associated with a given pathway element, augmenting pathway elements to include indicators for pricing, efficacy and/or toxicity of a treatment associated with a given treatment element, and augmenting the pathway with a connection to another pathway including providing a link to another pathway at a point in a given pathway that provides information for a related pathway.

Abstract: Compositions and methods for inhibits the binding of GTP to oncogenic mutant KRas are disclosed. These compositions may be used in method to treat a subject with cancer. In particular, the compositions may be used to treat cancers involving overactive Ras signaling.

Abstract: Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, affinity maturated single chain variable fragment (scFv) antibodies that bind TAG-72 on cancer cells are disclosed.

Abstract: Embodiments of the invention relate to a method and apparatus for displaying information. In a specific embodiment, at least two pluralities of voxel values for a corresponding at least two functions with respect to at least a portion of a subject can be obtained. The at least a portion of the subject can have a plurality of local volume elements, where the at least two pluralities of voxel values for the corresponding at least two functions each correspond to the plurality of local volume elements. In this way, there is a voxel value for each function for each local volume element of the portion of the subject. Each of the at least two pluralities of voxel values represents the value of the corresponding function of the at least two functions for the corresponding plurality of local volume elements. A representation is created where the value of one of the at least two functions is on a first axis and a count of voxels is on a second axis.

Abstract: Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill cancer cells that express TLR9 on their surface. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a TLR9-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

Abstract: The present disclosure relates to a method for diagnosing in a subject the progression from myelodysplastic syndrome (MDS) to acute myelogenous leukemia (AML). Also disclosed are methods of treating AML in a subject diagnosed by the disclosed methods.

Abstract: The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.

Abstract: Disclosed are methods for diagnosing a myelodysplastic syndrome (MDS) in a subject. In some embodiments, the method involves assaying a sample from the subject to detect inflammasome activation, wherein an increase in inflammasome activation in the sample compared to a control is an indication of MDS in the subject. The disclosed methods can further involve treating the subject for MDS if an increase in inflammasome activation is detected.

Abstract: A method and system for performing bone fusion and/or securing one or more bones, such as adjacent vertebra, are disclosed.

Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

Abstract: Systems and methods for storing large data sets, such as genetic sequence information. Within a “targeted subset” of positions with information, the system stores, both variant states and missing states at each position. Reference states are not stored, but are inferred within the targeted subset when neither a variant nor a missing state is stored at a given position. The absence of a variant state at a given position is assumed to be a reference state. The criteria for missing data are defined in pre-processing and are customizable based on the use case. For example, each data point may represent the genetic information of a sample at a position in the genome. The targeted subset may represent those positions that were included in a sequencing test.

Abstract: Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible Treg. In certain aspects, disclosed are compounds of Formula I-V.

Abstract: Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill TAG-72-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a TAG-72-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

Abstract: Novel compounds (small molecules) that potently and selectively inhibit MMP-13 (i.e., MMP-13 inhibitors) are used for treatment of multiple myeloma. The MMP-13 inhibitors described herein are highly selective for MMP-13 and when administered to an individual in need thereof, the compounds selectively kill multiple myeloma cells, reduce growth of multiple myeloma cells, inhibit multiple myeloma-induced osteoclastogenesis, and increase survival time in the individual.

Abstract: The present disclosure describes combination therapies for breast cancer comprising an oligonucleotide toll-like receptor 9 agonist and a PD-1 antagonist. In particular, the present disclosure describes combinations of a CpG-C type oligonucleotide and an anti-PD-1 antibody for the treatment of breast cancer. The combination may further comprise a taxane chemotherapeutic agent, in the presence or absence of a corticosteroid.

Abstract: An example method for segmenting an object contained in an image includes receiving an image including a plurality of pixels, transforming a plurality of characteristics of a pixel into respective neutrosophic set domains, calculating a neutrosophic similarity score for the pixel based on the respective neutrosophic set domains for the characteristics of the pixel, segmenting an object from background of the image using a region growing algorithm based on the neutrosophic similarity score for the pixel, and receiving a margin adjustment related to the object segmented from the background of the image.

Abstract: Disclosed are compositions and methods for targeted treatment of cancers, such as TLR9-expressing cancers. In particular, molecules containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, that target lytic peptides to TLR9-expressing malignant cells are disclosed.